FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1975997437> ?p ?o ?g. }

• W1975997437 endingPage "144" @default.
• W1975997437 startingPage "135" @default.
• W1975997437 abstract "<h2>Abstract</h2> background: Invasive aspergillosis is the most common invasive mould infection and a major cause of mortality in immunocompromised patients. Response to amphotericin B, the only antifungal agent licensed in the United States for the treatment of aspergillosis, is suboptimal. methods: A multicenter open study with strict entry criteria for invasive aspergillosis evaluated oral itraconazole (600 mg/d for 4 days followed by 400 mg/d) in patients with various underlying conditions. Response was based on clinical and radiologic criteria plus microbiology, histopathology, and autopsy data. Responses were categorized as complete, partial, or stable. Failure was categorized as an itraconazole failure or overall failure. results: Our study population consisted of 76 evaluable patients. Therapy duration varied from 0.3 to 97 weeks (median 46). At the end of treatment, 30 (39%) patients had a complete or partial response, and 3 (4%) had a stable response, and in 20 patients (26%), the protocol therapy was discontinued early (at 0.6 to 54.3 weeks) because of a worsening clinical course or death due to aspergillosis (itraconazole failure). Twenty-three (30%) patients withdrew for other reasons including possible toxicity (7%) and death due to another cause but without resolution of aspergillosis (20%). Itraconazole failure rates varied widely according to site of disease and underlying disease group: 14% for pulmonary and tracheobronchial disease, 50% for sinus disease, 63% for central nervous system disease, and 44% for other sites; 7% in solid organ transplant, 29% in allogeneic bone marrow transplant patients, and 14% in those with prolonged granulocytopenia (median 19 days), 44% in AIDS patients, and 32% in other host groups. The relapse rates among those who completed therapy and those who discontinued early for possible toxicity were 12% and 40%, respectively; all were still immunosuppressed. conclusion: Oral itraconazole is a useful alternative therapy for invasive aspergillosis with response rates apparently comparable to amphotericin B. Relapse in immunocompromised patients may be a problem. Controlled trials are necessary to fully assess the role of itraconazole in the treatment of invasive aspergillosis." @default.
• W1975997437 created "2016-06-24" @default.
• W1975997437 creator A5004070315 @default.
• W1975997437 creator A5004769805 @default.
• W1975997437 creator A5012854754 @default.
• W1975997437 creator A5013691610 @default.
• W1975997437 creator A5021143803 @default.
• W1975997437 creator A5027301429 @default.
• W1975997437 creator A5028777325 @default.
• W1975997437 creator A5039293604 @default.
• W1975997437 creator A5043299051 @default.
• W1975997437 creator A5046120735 @default.
• W1975997437 creator A5064143912 @default.
• W1975997437 creator A5068730364 @default.
• W1975997437 creator A5077951091 @default.
• W1975997437 creator A5082592696 @default.
• W1975997437 creator A5083752740 @default.
• W1975997437 date "1994-08-01" @default.
• W1975997437 modified "2023-10-01" @default.
• W1975997437 title "NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis" @default.
• W1975997437 cites W1979180336 @default.
• W1975997437 cites W1988195179 @default.
• W1975997437 cites W1990113680 @default.
• W1975997437 cites W1992995916 @default.
• W1975997437 cites W1997483245 @default.
• W1975997437 cites W2005315157 @default.
• W1975997437 cites W2025804022 @default.
• W1975997437 cites W2049470178 @default.
• W1975997437 cites W2056900917 @default.
• W1975997437 cites W2118833943 @default.
• W1975997437 cites W2141505400 @default.
• W1975997437 cites W2149472764 @default.
• W1975997437 cites W2153515355 @default.
• W1975997437 cites W2233665167 @default.
• W1975997437 cites W2317943467 @default.
• W1975997437 cites W4211019915 @default.
• W1975997437 cites W4302392220 @default.
• W1975997437 doi "https://doi.org/10.1016/0002-9343(94)90023-x" @default.
• W1975997437 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8059779" @default.
• W1975997437 hasPublicationYear "1994" @default.
• W1975997437 type Work @default.
• W1975997437 sameAs 1975997437 @default.
• W1975997437 citedByCount "434" @default.
• W1975997437 countsByYear W19759974372012 @default.
• W1975997437 countsByYear W19759974372013 @default.
• W1975997437 countsByYear W19759974372014 @default.
• W1975997437 countsByYear W19759974372015 @default.
• W1975997437 countsByYear W19759974372016 @default.
• W1975997437 countsByYear W19759974372017 @default.
• W1975997437 countsByYear W19759974372018 @default.
• W1975997437 countsByYear W19759974372019 @default.
• W1975997437 countsByYear W19759974372020 @default.
• W1975997437 countsByYear W19759974372021 @default.
• W1975997437 countsByYear W19759974372022 @default.
• W1975997437 countsByYear W19759974372023 @default.
• W1975997437 crossrefType "journal-article" @default.
• W1975997437 hasAuthorship W1975997437A5004070315 @default.
• W1975997437 hasAuthorship W1975997437A5004769805 @default.
• W1975997437 hasAuthorship W1975997437A5012854754 @default.
• W1975997437 hasAuthorship W1975997437A5013691610 @default.
• W1975997437 hasAuthorship W1975997437A5021143803 @default.
• W1975997437 hasAuthorship W1975997437A5027301429 @default.
• W1975997437 hasAuthorship W1975997437A5028777325 @default.
• W1975997437 hasAuthorship W1975997437A5039293604 @default.
• W1975997437 hasAuthorship W1975997437A5043299051 @default.
• W1975997437 hasAuthorship W1975997437A5046120735 @default.
• W1975997437 hasAuthorship W1975997437A5064143912 @default.
• W1975997437 hasAuthorship W1975997437A5068730364 @default.
• W1975997437 hasAuthorship W1975997437A5077951091 @default.
• W1975997437 hasAuthorship W1975997437A5082592696 @default.
• W1975997437 hasAuthorship W1975997437A5083752740 @default.
• W1975997437 hasBestOaLocation W19759974371 @default.
• W1975997437 hasConcept C126322002 @default.
• W1975997437 hasConcept C141071460 @default.
• W1975997437 hasConcept C16005928 @default.
• W1975997437 hasConcept C203014093 @default.
• W1975997437 hasConcept C2776391196 @default.
• W1975997437 hasConcept C2777071850 @default.
• W1975997437 hasConcept C2779548794 @default.
• W1975997437 hasConcept C2779629538 @default.
• W1975997437 hasConcept C2780908437 @default.
• W1975997437 hasConcept C2908647359 @default.
• W1975997437 hasConcept C535046627 @default.
• W1975997437 hasConcept C71924100 @default.
• W1975997437 hasConcept C90924648 @default.
• W1975997437 hasConcept C99454951 @default.
• W1975997437 hasConceptScore W1975997437C126322002 @default.
• W1975997437 hasConceptScore W1975997437C141071460 @default.
• W1975997437 hasConceptScore W1975997437C16005928 @default.
• W1975997437 hasConceptScore W1975997437C203014093 @default.
• W1975997437 hasConceptScore W1975997437C2776391196 @default.
• W1975997437 hasConceptScore W1975997437C2777071850 @default.
• W1975997437 hasConceptScore W1975997437C2779548794 @default.
• W1975997437 hasConceptScore W1975997437C2779629538 @default.
• W1975997437 hasConceptScore W1975997437C2780908437 @default.
• W1975997437 hasConceptScore W1975997437C2908647359 @default.
• W1975997437 hasConceptScore W1975997437C535046627 @default.
• W1975997437 hasConceptScore W1975997437C71924100 @default.

• next